Rigshospitalet

A groundbreaking clinical trial is investigating three different treatment approaches for intermediate-high risk pulmonary embolism (PE): standard heparin therapy, low-dose thrombolysis, and ultrasound-assisted thrombolysis (USAT). The study aims to enroll 210 patients and will evaluate the effectiveness of these interventions using refined Miller scores to measure thrombus reduction.

Glofitamab combined with polatuzumab vedotin shows high response rates and durable remissions in heavily pretreated relapsed/refractory large B-cell lymphoma (LBCL).

The phase 3 RUBY trial demonstrated that dostarlimab combined with carboplatin and paclitaxel significantly improved progression-free survival and overall survival in patients with advanced or recurrent endometrial cancer across multiple molecular subgroups.